SEMA3D and hepatocellular carcinoma: Notably, survival analysis for the training cohort reveals that HCC patients in the low Sema3d expression group had worse OS (1-, 3-, and 5-year OS: 88.41%, 59.06%, and 45.73% vs. 64.63%, 40.50%, and 27.66%) and DFS rates (1-, 3-, and 5-year DFS: 86.96%, 56.87%, and 37.68% vs. 63.06%, 36.94%, and 21.62%) than the patients in the high expression group (Figure 2C).